	US 11,938,178 B2
	Optimized epicutaneous vaccination
Hong Thai Pham, Bangkok (TH); Nathalie Donne, Allauch (FR); Pierre-Louis Herve, Montrouge (FR); and Lucie Mondoulet, Chatillon (FR)
Assigned to DBV TECHNOLOGIES, Montrouge (FR); and BIONET-ASIA CO., LTD, Bangkok (TH)
Appl. No. 17/258,758
Filed by DBV TECHNOLOGIES, Montrouge (FR); and BIONET-ASIA CO., LTD, Bangkok (TH)
PCT Filed Jul. 9, 2019, PCT No. PCT/EP2019/068324 § 371(c)(1), (2) Date Jan. 8, 2021, PCT Pub. No. WO2020/011746, PCT Pub. Date Jan. 16, 2020.
Claims priority of application No. 18305906 (EP), filed on Jul. 9, 2018; and application No. 18305907 (EP), filed on Jul. 9, 2018.
Prior Publication US 2021/0121556 A1, Apr. 29, 2021
Int. Cl. A61K 39/09 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 39/02 (2006.01); A61P 31/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/099 (2013.01) [A61K 9/0014 (2013.01); A61K 9/7023 (2013.01); A61P 31/04 (2018.01); A61K 2039/522 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01)]

21 Claims

1. A method for providing a boosting vaccination against a bacterial pathogen in a primed subject in need thereof, which comprises:

performing skin micro-perforation in a skin area in the subject with a laser microporator so as to form an array of micropores, the skin micro-perforation not altering the basal layer of the epidermis and the array of micropores extending from the surface of the skin through one or several epidermis layers, but without extending to the dermis, and

then epicutaneously administering an antigen from the bacterial pathogen on said skin area of the subject by means of a skin patch, wherein:

the skin patch is occlusive and comprises a backing suitable to create a hermetically closed condensation chamber on skin, and wherein the antigen is deposited on the skin facing side of said backing, in dry form, and optionally in combination with one or several pharmaceutically acceptable excipients.